Pharma Journalist -

ProBioGen AG announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company,…
Read More...

Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the…
Read More...

During the past several years, many strains of bacteria have become resistant to existing antibiotics, and very few new drugs have been added to the antibiotic arsenal. To help…
Read More...

GE Healthcare is launching a ready-to-run factory-in-a-box to speed up the production of viral vector based therapeutics, including viral vector based vaccines, oncolytic viruses and…
Read More...

Merck announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The…
Read More...

SAMDI Tech, Inc. has partnered with Enamine to expand the number of molecules in their small molecule compound libraries. Through the partnership, SAMDI Tech will be able to offer its…
Read More...

Shire plc announces that it has entered into a definitive agreement with Servier S.A.S. to sell its Oncology business for $2.4 billion. Shire's Oncology business includes in-market…
Read More...

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced that it has signed a collaborative agreement with Plexxikon Inc., the…
Read More...

Cardurion Pharmaceuticals announced it has entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve…
Read More...

Sobi has received approval from Health Canada for a reduced dosing frequency for Orfadin (nitisinone). Orfadin is approved in combination with dietary restriction of tyrosine and…
Read More...